Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01500 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Miguel Martín und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Gregorio Marañón, Universidad Complutense, GEICAM, CIBERONC, Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen, Fulvestrant. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines of systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly assigned 1:1 to giredestrant (30 mg oral once daily) or fulvestrant/aromatase inhibitor per local guidelines (+luteinizing hormone–releasing hormone agonist in pre-/perimenopausal women, and men) until disease progression/unacceptable toxicity. Stratification was by visceral versus nonvisceral disease, prior cyclin-dependent kinase 4/6 inhibitor, and prior fulvestrant. The primary end point was investigator-assessed progression-free survival (INV-PFS). RESULTS At clinical cutoff (February 18, 2022; median follow-up: 7.9 months; N = 303), the INV-PFS hazard ratio (HR) was 0.81 (95% CI, 0.60 to 1.10; P = .1757). In the prespecified secondary end point analysis of INV-PFS by ESR1 mutation (m) status in circulating tumor DNA–evaluable patients (n = 232), the HR in patients with a detectable ESR1m (n = 90) was 0.60 (95% CI, 0.35 to 1.03) versus 0.88 (95% CI, 0.54 to 1.42) in patients with no ESR1m detected (n = 142). Related grade 3-4 adverse events (AEs), serious AEs, and discontinuations due to AEs were balanced across arms. CONCLUSION Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Gregorio Marañón, Universidad Complutense, GEICAM, CIBERONC, Madrid, Spain.
- Garvan Institute of Medical Research, St Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Massachusetts General Hospital, Harvard Medical School, Boston, MA.
- Fudan University Cancer Institute, Shanghai, China.
- Harbin Medical University Cancer Hospital, Harbin, China.
ORCID-Profile: Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor, Aditya Bardia, Jiong Wu, Zbigniew Nowecki, Felipe Melo Cruz, Rustem Safin, Sung-Bae Kim, Alberto J Montero, Heather M Moore, Joohyuk Sohn
Zitieren
APA
Martín, M., Lim, E., Chavez-MacGregor, M., Bardia, A., Wu, J., Zhang, Q., Nowecki, Z., Cruz, F. M., Safin, R., Kim, S. B., Schem, C., Montero, A. J., Khan, S., Bandyopadhyay, R., Moore, H. M., Shivhare, M., Patre, M., Martinalbo, J., Roncoroni, L., …, & acelERA Breast Cancer Study Investigators (2024). Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01500
Vancouver
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01500
BibTeX
@article{Martn2024,
author = {Martín, Miguel and Lim, Elgene and Chavez-MacGregor, Mariana and Bardia, Aditya and Wu, Jiong and Zhang, Qingyuan and Nowecki, Zbigniew and Cruz, Felipe Melo and Safin, Rustem and Kim, Sung-Bae and Schem, Christian and Montero, Alberto J and Khan, Sarah and Bandyopadhyay, Reeti and Moore, Heather M and Shivhare, Mahesh and Patre, Monika and Martinalbo, Jorge and Roncoroni, Laura and Pérez-Moreno, Pablo Diego and Sohn, Joohyuk and acelERA Breast Cancer Study Investigators, acelERA Breast Cancer Study Investigators},
title = {Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01500}
}
EUVIMED